SOPHiA GENETICS prices $50M public offering on Nasdaq
What's the deal? SOPHiA GENETICS, a healthcare technology company that uses AI to analyse genomic data, has priced a $50M underwritten public offering on the Nasdaq. The company is selling 10,526,000 ordinary shares at $4.75 each — a slight discount to its recent trading price of $4.93.
TD Cowen is leading the deal as book-running manager, with Guggenheim SecuritiesDealroom has a profile for this one. Try Dealroom → as co-book-runner and BTIGDealroom has a profile for this one. Try Dealroom → and Craig-HallumDealroom has a profile for this one. Try Dealroom → as lead managers. The company also granted underwriters a 30-day option to buy up to 1,578,900 additional shares.
The offering is expected to close on 18 June 2026, subject to customary conditions.
Why now? The timing aligns with several strategic moves. In June 2026 SOPHiA GENETICS signed a memorandum of understanding with Memorial Sloan Kettering Cancer Center to form a joint venture in precision oncology diagnostics. A leadership transition is also underway — Ross Muken is set to become chief executive officer on 1 July 2026, with co-founder Dr Jurgi CamblongDealroom has a profile for this one. Try Dealroom → moving to chairman of the board.
The stock has gained nearly 69% over the 12 months to June 2026, giving the company a favourable window to raise capital.
What could go wrong? The offering price sits below the current trading price, which could signal dilution concerns for existing shareholders. Fresh capital will also need to translate into measurable growth — particularly as the company competes in the crowded health-tech and genomics space.
Leadership transitions always carry execution risk, especially when a co-founder steps back from the chief executive role.
The signal: SOPHiA GENETICS is classified as a late-stage company on Dealroom, yet its decision to raise capital through a discounted public offering — rather than private markets — underscores the thinning options for health-tech firms that went public during the 2021 boom and have since traded well below their IPO price. The Memorial Sloan Kettering joint venture could prove pivotal: securing a marquee clinical partner would help the company shift its narrative from platform provider to embedded diagnostics infrastructure, a positioning that commands far higher multiples in genomics.
Read more: Investing.com
